XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.3

Note 16 - Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		During the Three-Month
		Period Ended September 30, 2025
		Scours				Mastitis				Other				Total
Product sales		$	5,444,619			$	61,503			$	—			$	5,506,122
Costs of goods sold			3,100,872				42,152				—				3,143,024
Gross margin			2,343,747				19,351				—				2,363,098
Sales and marketing expenses			837,141				82,150				—				919,291
Product development expenses			88,894				575,642				29,775				694,311
Administrative expenses			—				—				729,421				729,421
Operating expenses			926,035				657,792				759,196				2,343,023
NET OPERATING INCOME (LOSS)		$	1,417,712			$	(638,441	)		$	(759,196	)		$	20,075

		During the Three-Month
		Period Ended September 30, 2024
		Scours				Mastitis				Other				Total
Product sales		$	5,951,344			$	60,229			$	—			$	6,011,573
Costs of goods sold			4,364,950				63,069				—				4,428,019
Gross margin			1,586,394				(2,840	)			—				1,583,554
Sales and marketing expenses			699,584				144,461				—				844,045
Product development expenses			59,140				690,052				36,944				786,136
Administrative expenses			—				—				528,267				528,267
Operating expenses			758,724				834,513				565,211				2,158,448
NET OPERATING INCOME (LOSS)		$	827,670			$	(837,353	)		$	(565,211	)		$	(574,894	)

		During the Nine-Month
		Period Ended September 30, 2025
		Scours				Mastitis				Other				Total
Product sales		$	19,871,621			$	146,554			$	—			$	20,018,175
Costs of goods sold			11,365,307				117,874				—				11,483,181
Gross margin			8,506,314				28,680				—				8,534,994
Sales and marketing expenses			2,259,124				212,911				—				2,472,035
Product development expenses			275,390				1,915,299				92,327				2,283,016
Administrative expenses			—				—				2,072,682				2,072,682
Operating expenses			2,534,514				2,128,210				2,165,009				6,827,733
NET OPERATING INCOME (LOSS)		$	5,971,800			$	(2,099,530	)		$	(2,165,009	)		$	1,707,261

		During the Nine-Month
		Period Ended September 30, 2024
		Scours				Mastitis				Other				Total
Product sales		$	18,602,054			$	139,986			$	—			$	18,742,040
Costs of goods sold			13,487,348				145,294				—				13,632,642
Gross margin			5,114,706				(5,308	)			—				5,109,398
Sales and marketing expenses			2,224,836				405,089				—				2,629,925
Product development expenses			154,233				2,821,525				103,431				3,079,189
Administrative expenses			—				—				1,661,838				1,661,838
Operating expenses			2,379,069				3,226,614				1,765,269				7,370,952
NET OPERATING INCOME (LOSS)		$	2,735,637			$	(3,231,922	)		$	(1,765,269	)		$	(2,261,554	)

		During the Year Ended
		December 31, 2024
		Scours				Mastitis				Other				Total
Product sales		$	26,314,251			$	178,918			$	—			$	26,493,169
Costs of goods sold			18,382,949				169,176				—				18,552,125
Gross margin			7,931,302				9,742				—				7,941,044
Product development expenses			243,578				3,493,298				161,706				3,898,582
Sales and marketing expenses			2,909,799				556,273				—				3,466,072
Administrative expenses			—				—				2,216,549				2,216,549
Operating expenses			3,153,377				4,049,571				2,378,255				9,581,203
NET OPERATING INCOME (LOSS)		$	4,777,925			$	(4,039,829	)		$	(2,378,255	)		$	(1,640,159	)

		During the Year Ended
		December 31, 2023
		Scours				Mastitis				Other				Total
Product sales		$	17,293,933			$	177,736			$	—			$	17,471,669
Costs of goods sold			13,453,514				148,871				—				13,602,385
Gross margin			3,840,419				28,865				—				3,869,284
Product development expenses			11,103				4,242,329				141,420				4,394,852
Sales and marketing expenses			2,447,137				641,078				—				3,088,215
Administrative expenses			—				—				2,134,295				2,134,295
Operating expenses			2,458,240				4,883,407				2,275,715				9,617,362
NET OPERATING INCOME (LOSS)		$	1,382,179			$	(4,854,542	)		$	(2,275,715	)		$	(5,748,078	)

Total Assets, Depreciation and Amortization, and Capital Expenditures [Table Text Block]

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2025		$	26,039,474			$	15,610,993			$	4,079,656			$	45,730,123
Total Assets as of September 30, 2024		$	23,672,583			$	16,798,955			$	3,977,335			$	44,448,873
Depreciation and amortization expense during the three-month period ended September 30, 2025		$	377,484			$	313,719			$	17,464			$	708,667
Depreciation and amortization expense during the three-month period ended September 30, 2024		$	346,430			$	319,815			$	19,682			$	685,927
Capital Expenditures during the three-month period ended September 30, 2025		$	582,304			$	11,020			$	600			$	593,924
Capital Expenditures during the three-month period ended September 30, 2024		$	87,286			$	1,126			$	—			$	88,412

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2025		$	26,039,474			$	15,610,993			$	4,079,656			$	45,730,123
Total Assets as of September 30, 2024		$	23,672,583			$	16,798,955			$	3,977,335			$	44,448,873
Depreciation and amortization expense during the nine-month period ended September 30, 2025		$	1,075,518			$	942,553			$	56,406			$	2,074,477
Depreciation and amortization expense during the nine-month period ended September 30, 2024		$	1,027,711			$	958,260			$	59,221			$	2,045,192
Capital Expenditures during the nine-month period ended September 30, 2025		$	1,056,490			$	18,772			$	2,871			$	1,078,133
Capital Expenditures during the nine-month period ended September 30, 2024		$	220,098			$	49,411			$	—			$	269,509

		Scours				Mastitis				Other				Total
Total Assets as of December 31, 2024		$	24,644,294			$	16,523,048			$	3,933,135			$	45,100,477
Total Assets as of December 31, 2023		$	24,735,413			$	17,827,839			$	1,244,850			$	43,808,102
Depreciation and amortization expense during the year ended December 31, 2024		$	1,373,815			$	1,277,218			$	78,814			$	2,729,847
Depreciation and amortization expense during the year ended December 31, 2023		$	1,365,988			$	1,287,600			$	86,032			$	2,739,620
Capital Expenditures during the year ended December 31, 2024		$	409,696			$	53,721			$	2,308			$	465,725
Capital Expenditures during the year ended December 31, 2023		$	1,096,819			$	795,694			$	—			$	1,892,513

X

- Definition

Tabular disclosure of Total Assets, Depreciation and Amortization, and Capital Expenditures.

+ References

No definition available.

+ Details

Name:	iccc_TotalAssetsDepreciationAndAmortizationAndCapitalExpendituresTableTextBlock
Namespace Prefix:	iccc_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration